Literature DB >> 25086129

Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: a retrospective analysis of 30 patients.

L van der Heijden1, M J L Mastboom1, P D S Dijkstra1, M A J van de Sande1.   

Abstract

We retrospectively reviewed 30 patients with a diffuse-type giant-cell tumour (Dt-GCT) (previously known as pigmented villonodular synovitis) around the knee in order to assess the influence of the type of surgery on the functional outcome and quality of life (QOL). Between 1980 and 2001, 15 of these tumours had been treated primarily at our tertiary referral centre and 15 had been referred from elsewhere with recurrent lesions. The mean follow-up was 64 months (24 to 393). Functional outcome and QOL were assessed with range of movement and the Knee injury and Osteoarthritis Outcome Score (KOOS), the Musculoskeletal Tumour Society (MSTS) score, the Toronto Extremity Salvage Score (TESS) and the SF-36 questionnaire. There was recurrence in four of 14 patients treated initially by open synovectomy. Local control was achieved after a second operation in 13 of 14 (93%). Recurrence occurred in 15 of 16 patients treated initially by arthroscopic synovectomy. These patients underwent a mean of 1.8 arthroscopies (one to eight) before open synovectomy. This achieved local control in 8 of 15 (53%) after the first synovectomy and in 12 of 15 (80%) after two. The functional outcome and QOL of patients who had undergone primary arthroscopic synovectomy and its attendant subsequent surgical procedures were compared with those who had had a primary open synovectomy using the following measures: range of movement (114º versus 127º; p = 0.03); KOOS (48 versus 71; p = 0.003); MSTS (19 versus 24; p = 0.02); TESS (75 versus 86; p = 0.03); and SF-36 (62 versus 80; p = 0.01). Those who had undergone open synovectomy needed fewer subsequent operations. Most patients who had been referred with a recurrence had undergone an initial arthroscopic synovectomy followed by multiple further synovectomies. At the final follow-up of eight years (2 to 32), these patients had impaired function and QOL compared with those who had undergone open synovectomy initially. We conclude that the natural history of Dt-GCT in patients who are treated by arthroscopic synovectomy has an unfavourable outcome, and that primary open synovectomy should be undertaken to prevent recurrence or residual disease. ©2014 The British Editorial Society of Bone & Joint Surgery.

Entities:  

Keywords:  Arthroscopy; Diffuse-type giant-cell tumor; Functional outcome; Open synovectomy; Pigmented villonodular synovitis; Quality of life

Mesh:

Year:  2014        PMID: 25086129     DOI: 10.1302/0301-620X.96B8.33608

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  12 in total

1.  Pigmented villonodular synovitis: a crowdsourcing study of two hundred and seventy two patients.

Authors:  Lizz van der Heijden; Sheila R Piner; Michiel Adrianus Josephus van de Sande
Journal:  Int Orthop       Date:  2016-05-12       Impact factor: 3.075

2.  Tenosynovial Giant Cell Tumors in Children: A Similar Entity Compared With Adults.

Authors:  Monique J L Mastboom; Floortje G M Verspoor; Daniël Uittenbogaard; Gerard R Schaap; Paul C Jutte; H W Bart Schreuder; Michiel A J van de Sande
Journal:  Clin Orthop Relat Res       Date:  2018-09       Impact factor: 4.176

3.  Arthroplasty for tenosynovial giant cell tumors.

Authors:  Floortje G M Verspoor; Gerjon Hannink; Anouk Scholte; Ingrid C M Van Der Geest; H W Bart Schreuder
Journal:  Acta Orthop       Date:  2016-06-30       Impact factor: 3.717

4.  Cryosurgery as Additional Treatment in Tenosynovial Giant Cell Tumors.

Authors:  F G M Verspoor; A Scholte; I C M van der Geest; G Hannink; H W B Schreuder
Journal:  Sarcoma       Date:  2016-12-26

5.  Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases.

Authors:  Monique J L Mastboom; Floortje G M Verspoor; Hans Gelderblom; Michiel A J van de Sande
Journal:  Case Rep Orthop       Date:  2017-06-28

6.  Higher incidence rates than previously known in tenosynovial giant cell tumors.

Authors:  Monique J L Mastboom; Floortje G M Verspoor; Arjan J Verschoor; Daniël Uittenbogaard; Banne Nemeth; Walter J B Mastboom; Judith V M G Bovée; P D Sander Dijkstra; H W Bart Schreuder; Hans Gelderblom; Michiel A J Van de Sande
Journal:  Acta Orthop       Date:  2017-08-08       Impact factor: 3.717

7.  Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.

Authors:  F G M Verspoor; M J L Mastboom; G Hannink; R G Maki; A Wagner; E Bompas; J Desai; A Italiano; B M Seddon; W T A van der Graaf; J-Y Blay; M Brahmi; L Eberst; S Stacchiotti; O Mir; M A J van de Sande; H Gelderblom; P A Cassier
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

8.  Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.

Authors:  Heather L Gelhorn; Sandra Tong; Kelly McQuarrie; Christina Vernon; Jennifer Hanlon; Grant Maclaine; William Lenderking; Xin Ye; Rebecca M Speck; Richard D Lackman; Susan V Bukata; John H Healey; Vicki L Keedy; Stephen P Anthony; Andrew J Wagner; Daniel D Von Hoff; Arun S Singh; Carlos R Becerra; Henry H Hsu; Paul S Lin; William D Tap
Journal:  Clin Ther       Date:  2016-04-01       Impact factor: 3.393

9.  The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life.

Authors:  Monique Josephine Mastboom; Rosa Planje; Michiel Adreanus van de Sande
Journal:  Interact J Med Res       Date:  2018-02-23

10.  Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease.

Authors:  John H Healey; Nicholas M Bernthal; Michiel van de Sande
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2020-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.